Burgdorf – Terumo Corporation (Terumo), a leading global manufacturer and distributor of medical devices, will fill its PLAJEX™ syringe with the drug Teribone™ and assemble it with the YpsoMate prefilled autoinjector from Ypsomed. Teribone™ is a Teriparatide for the treatment of osteoporosis. The drug was developed by Asahi Kasei Pharma (AKP) and will be launched in Japan.
The pre-filled Teribone™ autoinjector is based on Ypsomed's YpsoMate platform and is designed for subcutaneous injection of liquid drugs. Terumo assembles the YpsoMate with its proprietary PLAJEX™ syringe for administration of the drug. AKP received market approval for Teribone™ in September 2019 and is launching the drug in Japan in December 2019.
Teribone™ is indicated for the treatment of patients living with Osteoporosis. Osteoporosis is a condition in which the bones become weaker and more fragile. According to the World Health Organisation (WHO), around 200 million people live with Osteoporosis worldwide. To date, Teribone™ has been available in a lyophilized vial formulation, and administration has taken place in the doctor's office. With the launch of Teribone™ in Ypsomed's pre-filled 2-step YpsoMate autoinjector, patients now have the opportunity to administer the drug themselves at home twice a week, if the treating physician recommends it.
Ypsomed and Terumo have worked closely together to enhance the value of Teribone™. With the combination of the YpsoMate autoinjector and PLAJEX™, we are able to provide a new treatment option to patients,
says Tetsuya Kumei, Division President of the Alliance Division, General Hospital Company of Terumo Corporation.
The Teribone™ autoinjector is already the second commercial market entry with Terumo. We see a growing need for easy-to-use injection devices for home use to increase quality of life, patient adherence and thus reduce healthcare costs,
comments Ulrike Bauer, Senior Vice President Ypsomed Delivery Systems.
